Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the … Read more
Vericel Corporation (ATQP) - Total Assets
Latest total assets as of September 2025: €453.27 Million EUR
Based on the latest financial reports, Vericel Corporation (ATQP) holds total assets worth €453.27 Million EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Vericel Corporation - Total Assets Trend (2014–2024)
This chart illustrates how Vericel Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Vericel Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
Vericel Corporation's total assets of €453.27 Million consist of 49.2% current assets and 50.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 17.2% |
| Accounts Receivable | €61.38 Million | 14.2% |
| Inventory | €17.37 Million | 4.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €6.25 Million | 1.4% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Vericel Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vericel Corporation's current assets represent 49.2% of total assets in 2024, a decrease from 87.2% in 2014.
- Cash Position: Cash and equivalents constituted 17.2% of total assets in 2024, down from 63.8% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 6.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 14.2% of total assets.
Vericel Corporation Competitors by Total Assets
Key competitors of Vericel Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Vericel Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Vericel Corporation generates 0.55x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Vericel Corporation generates $ 2.39 in net profit.
Vericel Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.87 | 4.61 | 5.50 |
| Quick Ratio | 4.47 | 4.23 | 5.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €176.38 Million | € 149.17 Million | € 101.08 Million |
Vericel Corporation - Advanced Valuation Insights
This section examines the relationship between Vericel Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.63 |
| Latest Market Cap to Assets Ratio | 3.27 |
| Asset Growth Rate (YoY) | 22.4% |
| Total Assets | €432.72 Million |
| Market Capitalization | $1.42 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Vericel Corporation's assets at a significant premium ( 3.27x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Vericel Corporation's assets grew by 22.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Vericel Corporation (2014–2024)
The table below shows the annual total assets of Vericel Corporation from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €432.72 Million | +22.36% |
| 2023-12-31 | €353.66 Million | +29.54% |
| 2022-12-31 | €273.00 Million | +12.02% |
| 2021-12-31 | €243.71 Million | +18.53% |
| 2020-12-31 | €205.61 Million | +34.18% |
| 2019-12-31 | €153.24 Million | +29.11% |
| 2018-12-31 | €118.69 Million | +117.47% |
| 2017-12-31 | €54.58 Million | +12.30% |
| 2016-12-31 | €48.60 Million | +41.65% |
| 2015-12-31 | €34.31 Million | -27.89% |
| 2014-12-31 | €47.58 Million | -- |